×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis
mechanism
3,471 words
KG: ent-dise-93f3d65f
2026-03-24
kind:mechanism
section:mechanisms
state:published
Contents
TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis
⚙
Mechanism Info
Name
TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis
Summary
Comprehensive review of TDP-43 proteinopathy in ALS, including molecular mechanisms, genetic factors, therapeutic targets, and clinical implications.
Knowledge Graph
Related Hypotheses (18)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Cryptic Exon Silencing Restoration
Score: 0.46
Cross-Seeding Prevention Strategy
Score: 0.45
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
Stress Granule Phase Separation Modulators
Score: 0.49
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43
Score: 0.60
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
APOE Isoform Conversion Therapy
Score: 0.44
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.42
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.37
Show 13 more
Related Analyses (30)
What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed
How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed
How does APOE4 mechanistically increase TDP-43 pathology fre
neurodegeneration · failed
What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed
What mechanisms underlie TDP-43's contribution to cognitive
neurodegeneration · failed
What determines the selectivity and efficiency of intercellu
neurodegeneration · completed
What are the specific design principles for small molecules
medicinal chemistry · failed
Does DNAJB6 directly inhibit cross-seeding between tau, α-sy
neurodegeneration · failed
What is the therapeutic window between insufficient and toxi
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed
What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
What are the molecular signatures that distinguish protectiv
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Show 25 more
Related Experiments (30)
cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95
TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90
TDP-43 mitochondrial invasion and DNA release via mPTP
exploratory · proposed · Score: 0.90
TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90
cGAS/STING pathway validation in TDP-43 mutant mice
validation · proposed · Score: 0.85
TDP-43 pathology prevalence and distribution in AD cases
exploratory · proposed · Score: 0.80
APOE4 association with TDP-43 pathology in AD
exploratory · proposed · Score: 0.75
Cognitive impact of TDP-43 pathology in AD patients
clinical · proposed · Score: 0.70
s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
Presymptomatic GRN Carrier Intervention Timing — Biomarker-G
clinical · proposed · Score: 0.40
Prion Strain Diversity and Selective Vulnerability in CJD
clinical · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
Endothelium-specific TBK1 knockdown in atherosclerosis model
validation · proposed · Score: 0.90
TBK1-PAK1IP1-PAK1 signaling pathway analysis
exploratory · proposed · Score: 0.90
LC-MS/Western blot analysis of TBK1 in atherosclerotic arter
exploratory · proposed · Score: 0.80
Show 25 more